Bulimia Nervosa care options

We show care options we have checked for this need. We may not have all options. This page cannot tell you which is best for you.

Published Sep 21, 2026Revision 2 · EveryOptionEnglish (United States)

Published treatment options

These are the options we have published. This order does not say which is best for you.

3 published options

Assessment for Bulimia Nervosa

Cognitive Behavioral Therapy
Published assessmentPublished Oct 6, 2026 · revision 2
Fluoxetine
Published assessmentPublished Sep 20, 2026 · revision 1
Sertraline
Published assessmentPublished Sep 21, 2026 · revision 1

Not reviewed means no current published assessment for the exact pair. No published conclusion means an assessment exists without a research conclusion. Neither establishes benefit or no benefit.

Compare published options

Cognitive Behavioral Therapy for Bulimia Nervosa

This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.

Research suggests benefit in this exact scope

Published Oct 6, 2026 · revision 2

What research says

NICE says individual eating-disorder-focused CBT can be considered for adults when bulimia-nervosa-focused guided self-help is unacceptable, contraindicated, or ineffective after four weeks. This assessment does not compare every option or determine personal suitability.

Official guideline documents · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Completeness: Not assessed
Need: bulimia nervosa
Population: NICE guideline populations described in recommendation 1.5

Source collection coverage: global

Pointer: /document/recommendation

Open source

Delivery and time commitment

Under England’s NICE guideline NG69 (recommendation 1.5.5), a course of individual eating-disorder-focused CBT for adults with bulimia nervosa typically involves up to 20 sessions over 20 weeks, and twice-weekly sessions may be considered early in treatment. These are guideline expectations for adults; a local provider’s schedule and an individual’s needs may differ.

Official guideline documents · checked Oct 6, 2026

Relationship: supports the attributed typical course length and early session frequency

Statement scope

Delivery: typically up to 20 sessions over 20 weeks; consider twice-weekly sessions in the first phase
Formulation or format: individual CBT-ED
Guideline: NG69
Indication: bulimia nervosa
Issuer: National Institute for Health and Care Excellence
Population: adults with bulimia nervosa
Recommendation: 1.5.5

Source collection coverage: global

Pointer: /document/recommendation

Open source

Read the exact scope and sources

Fluoxetine for Bulimia Nervosa

This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

What research says

The retained fluoxetine label reports three multicenter studies for bulimia nervosa; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Jurisdiction: United States label
Need: Bulimia Nervosa
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Supporting passage: The effectiveness of fluoxetine for the treatment of bulimia was demonstrated in two 8-week and one 16-week, multicenter, parallel-group studies of adult outpatients meeting DSM-III-R criteria for bulimia.

Open source

Read the exact scope and sources

Sertraline for Bulimia Nervosa

This assessment belongs to this exact Treatment and Need. It does not extend its conclusion to other populations or formats.

Promising, with important evidence limits

Published Sep 21, 2026 · revision 1

What research says

An open-access evidence review reports one 12-week placebo-controlled study in outpatients with bulimia nervosa that found fewer binge-eating crises and purging episodes with sertraline; one older study is promising but limited evidence. This assessment does not compare every option or determine personal suitability.

PubMed Central open-access full text · checked Oct 16, 2026

Relationship: supports bounded conclusion

Statement scope

Completeness: Not assessed
Need: bulimia nervosa
Population: outpatients with bulimia nervosa as described by the evidence review

Source collection coverage: global

Pointer: /document/passage

Open source

Read the exact scope and sources

Summary

The retained DailyMed label reports multicenter fluoxetine studies for bulimia nervosa; this page preserves that label-defined evidence scope.

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: supports bounded summary

Statement scope

Jurisdiction: United States label
Need: Bulimia Nervosa
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Open source

Coverage

These are the three options EveryOption has published for bulimia nervosa: fluoxetine, cognitive behavioral therapy, and sertraline. This is not a complete list of treatments.

PubMed Central open-access full text · checked Oct 16, 2026

Relationship: supports published option coverage

Statement scope

Completeness: Not assessed
Need: bulimia nervosa
Population: outpatients with bulimia nervosa as described by the evidence review

Source collection coverage: global

Pointer: /document/passage

Open source

DailyMed fluoxetine hydrochloride label · checked Oct 16, 2026

Relationship: supports published option coverage

Statement scope

Jurisdiction: United States label
Need: Bulimia Nervosa
Population: source-defined study populations

Source collection coverage: country:US

Pointer: /sections/4

Open source

Official guideline documents · checked Oct 16, 2026

Relationship: supports published option coverage

Statement scope

Completeness: Not assessed
Need: bulimia nervosa
Population: NICE guideline populations described in recommendation 1.5

Source collection coverage: global

Pointer: /document/recommendation

Open source

Access

These are the options and access paths EveryOption has published for Denver for Bulimia Nervosa. This is not complete coverage of the condition or the city.

Provider-owned websites · checked Oct 16, 2026

Relationship: supports Denver access navigation

Statement scope